



Universiteit  
Leiden  
The Netherlands

## Genetic and clinical pharmacology studies in GBA1-associated Parkinson's disease

Heijer, J.M. den

### Citation

Heijer, J. M. den. (2022, March 30). *Genetic and clinical pharmacology studies in GBA1-associated Parkinson's disease*. Retrieved from <https://hdl.handle.net/1887/3281326>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3281326>

**Note:** To cite this publication please use the final published version (if applicable).





# **GENETIC AND CLINICAL PHARMACOLOGY STUDIES IN *GBA1*-ASSOCIATED PARKINSON'S DISEASE**

PROEFSCHRIFT

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,  
op gezag van rector magnificus prof.dr.ir. H. Bijl,  
volgens besluit van het college voor promoties  
te verdedigen op woensdag 30 maart 2022

klokke 16:15 uur

DOOR

Jonas Matthias den Heijer

geboren te Roermond

in 1991

*PROMOTORES*

Prof. dr. G.J. Groeneveld

Prof. dr. J.J. van Hilten

*LEDEN PROMOTIECOMMISSIE*

Prof. dr. F. Baas

Prof. dr. J.M.A. van Gerven

Dr. W.D.J. van de Berg, Amsterdam UMC

Dr. B.P.C. van de Warrenburg, Radboud UMC

DESIGN: Caroline de Lint, Den Haag (caro@delint.nl)

COVER: Folkert van Meurs (FvMeurs@chdr.nl)

*Photography used under the Unsplash License, for cover design: ('African fish eagle lunching' by Birger Strahl; 'Lioness staredown' by Harshil Gudka; 'Woman' by Icons8 Team).*

Publication of this thesis was financially supported by the foundation Centre for Human Drug Research (CHDR) in Leiden, the Netherlands

<b>Chapter 1</b>	Introduction; adapted and updated version of ‘New insights into the pathobiology of Parkinson’s disease and possibilities for pharmacotherapy’ – 8
<b>Chapter 2</b>	A large-scale full <i>GBA1</i> gene screening in Parkinson’s Disease in the Netherlands – 12
<b>Chapter 3</b>	False negatives in <i>GBA1</i> sequencing due to polymerase dependent allelic imbalance – 22
<b>Chapter 4</b>	Experience in genetic counseling for <i>GBA1</i> variants in Parkinson’s Disease – 58
<b>Chapter 5</b>	Intronic haplotypes in <i>GBA</i> modify age at diagnosis of Parkinson’s: Replication in a subgroup – 66
<b>Chapter 6</b>	Preparing for <i>GBA1</i> -targeting Parkinson’s disease trials: a biomarker study in patients with <i>GBA1</i> -Parkinson’s disease and healthy controls – 72
<b>Chapter 7</b>	A randomized single and multiple ascending dose study in healthy volunteers of LTI-291, a centrally penetrant glucocerebrosidase activator – 104
<b>Chapter 8</b>	A phase 1B trial in <i>GBA1</i> -associated Parkinson’s disease of LTI-291, a centrally-penetrant glucocerebrosidase activator – 130
<b>Chapter 9</b>	Discussion – 154
<b>Chapter 10</b>	Summary in Dutch – 160
<b>Appendices</b>	Curriculum Vitae – 165 List of publications – 166 Dankwoord – 168